41
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Ibuprofen alters human testicular physiology to produce a state of compensated hypogonadism

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          Concern has been raised over declining male reproductive health in humans. Our study addresses this issue by extending data showing antiandrogen effects of analgesics and suggests that such compounds may be involved in adult male reproductive problems. Using a unique combination of a randomized, controlled clinical trial and ex vivo and in vitro approaches, we report a univocal depression of important aspects of testicular function, including testosterone production, after use of over-the-counter ibuprofen. The study shows that ibuprofen use results in selective transcriptional repression of endocrine cells in the human testis. This repression results in the elevation of the stimulatory pituitary hormones, resulting in a state of compensated hypogonadism, a disorder associated with adverse reproductive and physical health disorders.

          Abstract

          Concern has been raised over increased male reproductive disorders in the Western world, and the disruption of male endocrinology has been suggested to play a central role. Several studies have shown that mild analgesics exposure during fetal life is associated with antiandrogenic effects and congenital malformations, but the effects on the adult man remain largely unknown. Through a clinical trial with young men exposed to ibuprofen, we show that the analgesic resulted in the clinical condition named “compensated hypogonadism," a condition prevalent among elderly men and associated with reproductive and physical disorders. In the men, luteinizing hormone (LH) and ibuprofen plasma levels were positively correlated, and the testosterone/LH ratio decreased. Using adult testis explants exposed or not exposed to ibuprofen, we demonstrate that the endocrine capabilities from testicular Leydig and Sertoli cells, including testosterone production, were suppressed through transcriptional repression. This effect was also observed in a human steroidogenic cell line. Our data demonstrate that ibuprofen alters the endocrine system via selective transcriptional repression in the human testes, thereby inducing compensated hypogonadism.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: not found

          Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study.

          The diagnosis of late-onset hypogonadism (LOH) in older men with age-related declines in testosterone (T) is currently not well characterized. Our objective was to investigate whether different forms of hypogonadism can be distinguished among aging men. The study was a cross-sectional survey on 3369 community-dwelling men aged 40-79 yr in eight European centers. Four groups of subjects were defined: eugonadal (normal T and normal LH), secondary (low T and low/normal LH), primary (low T and elevated LH), and compensated (normal T and elevated LH) hypogonadism. Relationships between the defined gonadal status with potential risk factors and clinical symptoms were investigated by multilevel regression models. Among the men, 11.8, 2.0, and 9.5% were classified into the secondary, primary, and compensated hypogonadism categories, respectively. Older men were more likely to have primary [relative risk ratio (RRR) = 3.04; P < 0.001] and compensated (RRR = 2.41; P < 0.001) hypogonadism. Body mass index of 30 kg/m(2) or higher was associated with secondary hypogonadism (RRR = 8.74; P < 0.001). Comorbidity was associated with both secondary and primary hypogonadism. Sexual symptoms were more prevalent in secondary and primary hypogonadism, whereas physical symptoms were more likely in compensated hypogonadism. Symptomatic elderly men considered to have LOH can be differentiated on the basis of endocrine and clinical features and predisposing risk factors. Secondary hypogonadism is associated with obesity and primary hypogonadism predominately with age. Compensated hypogonadism can be considered a distinct clinical state associated with aging. Classification of LOH into different categories by combining LH with T may improve the diagnosis and management of LOH.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Testosterone and Cardiovascular Disease.

            Testosterone (T) is the principal male sex hormone. As men age, T levels typically fall. Symptoms of low T include decreased libido, vasomotor instability, and decreased bone mineral density. Other symptoms may include depression, fatigue, erectile dysfunction, and reduced muscle strength/mass. Epidemiology studies show that low levels of T are associated with more atherosclerosis, coronary artery disease, and cardiovascular events. However, treating hypogonadism in the aging male has resulted in discrepant results in regard to its effect on cardiovascular events. Emerging studies suggest that T may have a future role in treating heart failure, angina, and myocardial ischemia. A large, prospective, long-term study of T replacement, with a primary endpoint of a composite of adverse cardiovascular events including myocardial infarction, stroke, and/or cardiovascular death, is needed. The Food and Drug Administration recently put additional restrictions on T replacement therapy labeling and called for additional studies to determine its cardiac safety.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Gonadotropin-releasing hormone receptors.

              GnRH and its analogs are used extensively for the treatment of hormone-dependent diseases and assisted reproductive techniques. They also have potential as novel contraceptives in men and women. A thorough delineation of the molecular mechanisms involved in ligand binding, receptor activation, and intracellular signal transduction is kernel to understanding disease processes and the development of specific interventions. Twenty-three structural variants of GnRH have been identified in protochordates and vertebrates. In many vertebrates, three GnRHs and three cognate receptors have been identified with distinct distributions and functions. In man, the hypothalamic GnRH regulates gonadotropin secretion through the pituitary GnRH type I receptor via activation of G(q). In-depth studies have identified amino acid residues in both the ligand and receptor involved in binding, receptor activation, and translation into intracellular signal transduction. Although the predominant coupling of the type I GnRH receptor in the gonadotrope is through productive G(q) stimulation, signal transduction can occur via other G proteins and potentially by G protein-independent means. The eventual selection of intracellular signaling may be specifically directed by variations in ligand structure. A second form of GnRH, GnRH II, conserved in all higher vertebrates, including man, is present in extrahypothalamic brain and many reproductive tissues. Its cognate receptor has been cloned from various vertebrate species, including New and Old World primates. The human gene homolog of this receptor, however, has a frame-shift and stop codon, and it appears that GnRH II signaling occurs through the type I GnRH receptor. There has been considerable plasticity in the use of different GnRHs, receptors, and signaling pathways for diverse functions. Delineation of the structural elements in GnRH and the receptor, which facilitate differential signaling, will contribute to the development of novel interventive GnRH analogs.
                Bookmark

                Author and article information

                Journal
                Proc Natl Acad Sci U S A
                Proc. Natl. Acad. Sci. U.S.A
                pnas
                pnas
                PNAS
                Proceedings of the National Academy of Sciences of the United States of America
                National Academy of Sciences
                0027-8424
                1091-6490
                23 January 2018
                8 January 2018
                8 January 2018
                : 115
                : 4
                : E715-E724
                Affiliations
                [1] aDanish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen , 1165 Copenhagen, Denmark;
                [2] bUniversité de Rennes I , Inserm, EHESP-School of Public Health, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, F-35000 Rennes, France;
                [3] cInstitute of Sports Medicine, Department of Orthopaedic Surgery M, Bispebjerg Hospital , 2400 Copenhagen NV, Denmark;
                [4] dCenter for Healthy Aging, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen , 1165 Copenhagen, Denmark;
                [5] eDTU Bio and Health Informatics, Technical University of Denmark , 2800 Kongens Lyngby, Denmark;
                [6] fDepartment of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen , 1165 Copenhagen, Denmark;
                [7] gL'Université Nantes Angers Le Mans (LUNAM), Oniris, UMR 1329 INRA Laboratoire d'Etude des Résidus et Contaminants dans les Aliments (LABERCA), F-44307 Nantes, France;
                [8] hUnité de coordination hospitalière des prélèvements d’organes et de tissus, Centre Hospitalier Universitaire de Rennes, 35000 Rennes, France;
                [9] iDepartment of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen , 1165 Copenhagen, Denmark;
                [10] jDepartment of Environmental Medicine, University of Southern Denmark , 5000 Odense, Denmark;
                [11] kDepartment of Biology, Faculty of Science, University of Copenhagen , 2100 Copenhagen, Denmark;
                [12] lInstitute of Metagenomics , BGI-Shenzhen, Shenzhen 518083, China
                Author notes
                2To whom correspondence may be addressed. Email: david.moebjerg.boslev.kristensen@ 123456regionh.dk or bernard.jegou@ 123456inserm.fr .

                Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved December 1, 2017 (received for review August 31, 2017)

                Author contributions: D.M.K., C.D.-L., A.L.M., M.D.D., S.M.-G., M.K., A.J., and B.J. designed research; D.M.K., C.D.-L., A.L.M., M.D.D., C.H.H., B.S., J.-P.A., B.L.B., C.P., L.L., S.M.-G., M.K., and A.J. performed research; D.M.K., S.B., and B.J. contributed new reagents/analytic tools; D.M.K., C.D.-L., F.D.M., C.H.H., B.S., J.-P.A., B.L.B., C.P., A.H.-S., T.K.J., L.L., S.M.-G., K.K., S.B., M.K., A.J., and B.J. analyzed data; and D.M.K., C.D.-L., and B.J. wrote the paper.

                1D.M.K. and C.D.-L. contributed equally to this work.

                Author information
                http://orcid.org/0000-0003-0657-1632
                http://orcid.org/0000-0002-6024-0917
                Article
                201715035
                10.1073/pnas.1715035115
                5789927
                29311296
                7cbc3bfc-2c8c-4735-be76-39cea9af4f42
                Copyright © 2018 the Author(s). Published by PNAS.

                This open access article is distributed under Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND).

                History
                Page count
                Pages: 10
                Funding
                Funded by: Nordea-fonden (Nordea Foundation) 501100004825
                Award ID: Healthy Ageing grant
                Funded by: Sundhed og Sygdom, Det Frie Forskningsråd (FSS, DFF) 100008392
                Award ID: 10-081087
                Funded by: Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) 501100007543
                Award ID: AAP-2012-037
                Categories
                PNAS Plus
                Biological Sciences
                Medical Sciences
                PNAS Plus

                ibuprofen,endocrine disruption,reproduction,hypogonadism,endocrinology

                Comments

                Comment on this article